South Korean biotech firms are making a notable presence at the American Association for Cancer Research (AACR) annual meeting in 2026, highlighting advancements in oncology therapeutics and manufacturing capabilities.
Nanoentek, a South Korean pharmaceutical company, confirmed its participation in the AACR 2026 conference, where it will showcase developments in its pipeline, particularly focusing on innovative drug delivery systems and RNA-based therapies.
Meanwhile, Samsung Biologics announced its attendance at the same event, emphasizing its role as a global contract development and manufacturing organization (CDMO). The company aims to leverage its CRDMO (contract research, development, and manufacturing organization) capabilities to attract international clients seeking end-to-end solutions for biologic drug production.
Another South Korean firm, Quriosys, unveiled its ‘Celloger Stack-H’ technology at the AACR meeting—a scalable cell culture system designed for large-scale production of biologics. The platform is positioned to support growing demand for efficient and high-yield manufacturing in the biopharmaceutical sector.
Collectively, these appearances underscore South Korea’s expanding footprint in the global oncology and biomanufacturing landscapes, with companies using the AACR forum to demonstrate technical competitiveness and seek strategic partnerships.
